MX367858B - Péptidos de conotoxina, composiciones farmacéuticas y usos de los mismos. - Google Patents

Péptidos de conotoxina, composiciones farmacéuticas y usos de los mismos.

Info

Publication number
MX367858B
MX367858B MX2015016492A MX2015016492A MX367858B MX 367858 B MX367858 B MX 367858B MX 2015016492 A MX2015016492 A MX 2015016492A MX 2015016492 A MX2015016492 A MX 2015016492A MX 367858 B MX367858 B MX 367858B
Authority
MX
Mexico
Prior art keywords
conotoxin peptides
pharmaceutical compositions
analog conotoxin
peptides
contoxin
Prior art date
Application number
MX2015016492A
Other languages
English (en)
Other versions
MX2015016492A (es
Inventor
michael mcintosh J
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of MX2015016492A publication Critical patent/MX2015016492A/es
Publication of MX367858B publication Critical patent/MX367858B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a los péptidos de conotoxina análogos de un péptido de a-conotoxina RgIA. Estos péptidos de conotoxina análogos bloquean el subtipo a9a10 del receptor nicotínico de acetilcolina (nAChR) y se pueden utilizar para tratar el dolor, condiciones inflamatorias, inflamación y/o cáncer.
MX2015016492A 2013-05-31 2014-05-30 Péptidos de conotoxina, composiciones farmacéuticas y usos de los mismos. MX367858B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829633P 2013-05-31 2013-05-31
US201361843135P 2013-07-05 2013-07-05
PCT/US2014/040374 WO2014194284A1 (en) 2013-05-31 2014-05-30 Conotoxin peptides, pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
MX2015016492A MX2015016492A (es) 2016-07-14
MX367858B true MX367858B (es) 2019-09-09

Family

ID=51989449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016492A MX367858B (es) 2013-05-31 2014-05-30 Péptidos de conotoxina, composiciones farmacéuticas y usos de los mismos.

Country Status (11)

Country Link
US (1) US10633417B2 (es)
EP (1) EP3003344B1 (es)
JP (1) JP6681826B2 (es)
KR (1) KR20160019469A (es)
CN (1) CN105377286B (es)
AU (1) AU2014273883B9 (es)
CA (1) CA2913993A1 (es)
HK (1) HK1221425A1 (es)
MX (1) MX367858B (es)
TW (1) TWI686205B (es)
WO (1) WO2014194284A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215172B1 (en) * 2014-11-07 2023-04-26 Kineta Chronic Pain, Llc. Modifications and uses of conotoxin peptides
CN105985410B (zh) * 2015-02-16 2019-11-29 海南大学 芋螺肽、其药物组合物及用途
US10947274B1 (en) * 2018-05-01 2021-03-16 University Of Utah Research Foundation Synthetic analgesic peptides of RgIA analogs
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
CN113493502B (zh) * 2020-04-01 2023-09-12 广西大学 α-芋螺毒素肽TxIE、其药物组合物及用途
CN114805488B (zh) * 2021-01-29 2023-05-30 李威 一种靶向神经元烟碱型乙酰胆碱受体的新型多肽分子nAChR_BP及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4569967A (en) 1983-10-24 1986-02-11 The Salk Institute For Biological Studies Synthesis of N-substituted peptide amides
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
ATE190633T1 (de) 1993-04-27 2000-04-15 Cytotherapeutics Inc Membran aus einem acrylnitrilpolymer
CA2166116A1 (en) 1993-06-23 1995-01-12 John F. Mills Method and apparatus for sealing implantable, membrane encapsulation devices
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5595972A (en) * 1993-06-29 1997-01-21 University Of Utah Research Foundation Conotoxin peptides
US5432155A (en) * 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
DK0802800T3 (da) 1993-08-12 2002-10-07 Neurotech Sa Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5858747A (en) 1994-07-20 1999-01-12 Cytotherapeutics, Inc. Control of cell growth in a bioartificial organ with extracellular matrix coated microcarriers
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
IN181898B (es) 1995-06-07 1998-10-24 Cytotherapeutics Inc
AU7204996A (en) 1995-10-02 1997-04-28 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
US5844077A (en) 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US5866682A (en) * 1997-05-15 1999-02-02 University Of Utah Research Foundation Conopeptides AuIA, AuIB and AuIC
WO1999033482A1 (en) * 1997-12-31 1999-07-08 University Of Utah Research Foundation Uses of alpha-conotoxin peptides
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
AU778353B2 (en) * 1999-01-22 2004-12-02 Cognetix, Inc. Alpha-conotoxin peptides
US6797808B1 (en) * 1999-01-29 2004-09-28 University Of Utah Research Foundation α-conotoxin peptides
US6767896B1 (en) * 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
JP2002536970A (ja) * 1999-02-04 2002-11-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション タウ−コノトキシン・ペプチド
CA2396529A1 (en) * 1999-12-30 2001-07-12 University Of Utah Research Foundation O-superfamily conotoxin peptides
US6767895B2 (en) * 2000-06-30 2004-07-27 Cognetix, Inc. I-superfamily conotoxins
US6727226B2 (en) * 2000-07-21 2004-04-27 University Of Utah Research Foundation Mu-conopeptides
US20030109670A1 (en) * 2001-02-09 2003-06-12 University Of Utah Research Foundation Cone snail peptides
US7387997B2 (en) * 2004-11-09 2008-06-17 University Of Utah α-conotoxin MII analogues
CA2566832A1 (en) * 2006-04-13 2007-10-13 The University Of Queensland Cyclised alpha-conotoxin peptides
US9284358B2 (en) * 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2008011006A2 (en) * 2006-07-18 2008-01-24 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US8765677B2 (en) * 2009-09-21 2014-07-01 The University Of Queensland Omega conotoxin peptides
US9469674B2 (en) * 2012-08-07 2016-10-18 Hainan University α-conotoxin peptide, pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
MX2015016492A (es) 2016-07-14
AU2014273883B2 (en) 2019-11-07
TWI686205B (zh) 2020-03-01
JP6681826B2 (ja) 2020-04-15
JP2016520620A (ja) 2016-07-14
CN105377286B (zh) 2021-07-02
US10633417B2 (en) 2020-04-28
AU2014273883A1 (en) 2015-12-17
HK1221425A1 (zh) 2017-06-02
CN105377286A (zh) 2016-03-02
KR20160019469A (ko) 2016-02-19
EP3003344B1 (en) 2020-11-25
EP3003344A1 (en) 2016-04-13
AU2014273883B9 (en) 2020-06-18
EP3003344A4 (en) 2016-12-28
WO2014194284A1 (en) 2014-12-04
US20160122388A1 (en) 2016-05-05
TW201503897A (zh) 2015-02-01
CA2913993A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
NZ630542A (en) Methods of treating a tauopathy
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX2015016492A (es) Peptidos de y conotoxina, composicion farmaceutica y usos de los mismos.
GB201209609D0 (en) New compounds
CL2015002897A1 (es) Inhibidores de bace1
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
PH12018501114A1 (en) Polypeptides inhibiting cd40l
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
KR101894521B9 (ko) 흉터치료를 위한 국소용 약학적 조성물
GB2527233A (en) Composition comprising hydrocortisone
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
CL2012001926A1 (es) Compuestos derivados de 5-(etinil)-pirimidinas, inhibidores de quinasa, en particular de pi3ka y mtor, como agentes antiproliferativos; composicion farmaceutica; y su uso para el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.

Legal Events

Date Code Title Description
FG Grant or registration